Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users.

Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. Abstract Text:

Alan Neaigus,V Anna Gyarmathy,Mingfang Zhao,Maureen Miller,Samuel R Friedman,Don C Des Jarlais,

BACKGROUND: Many heroin users do not inject drugs but may still be at risk of infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV), via sexual or other noninjection-related activity. METHODS: Noninjecting heroin users (NIUs) in New York City who were recruited and prospectively followed during March 1996-February 2003 were tested for anti-HIV, anti-hepatitis B core antigen, and anti-HCV and were interviewed about their sexual and other noninjecting risk. A seroconversion is represented by the first positive test result after the last negative test result. Hazard ratios (HRs) (P<.05) were estimated by use of Cox proportional hazards regression. RESULTS: Of 253 HIV-negative participants, 2 seroconverted (0.29/100 person-years at risk [pyar]); of 184 HBV-negative participants, 16 (3.3/100 pyar); and, of 219 HCV-negative participants, 16 (2.7/100 pyar). Independent predictors of seroconversion were, for HBV, being a female who engages in unprotected receptive anal sex (HR, 6.8), having short-term sex partners (HR, 6.2), and being a male with male sex partners (HR, 5.7); for HCV, being a male who receives money/drugs for sex (HR, 5.6) and sharing noninjecting crack-use equipment (HR, 4.5). CONCLUSIONS: NIUs are at considerable risk of HBV infection via high-risk sex; and, for HCV, via high-risk sexual activity and the sharing of noninjecting crack-use equipment. Interventions in NIUs must seek to reduce high-risk sexual activity and the sharing of noninjecting drug-use equipment.

Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. Publishing Authors By Initials

A Neaigus,VA Gyarmathy,M Zhao,M Miller,SR Friedman,DC Des Jarlais,

For similar bacterial infections and mycoses: infection: sexually transmitted diseases research abstracts see: bacterial infections and mycoses: infection: sexually transmitted diseases research

PUBMED ID PMID:

MEDLINE DATE:

Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The Journal of infectious diseases

VOLUME: 195

Page Numbers: 1052-61

Journal Abbreviation: J. Infect. Dis.

ISSN: 0022-1899

DAY: 23

MONTH: 02

YEAR: 2007

Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 413675

Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. Keywords Mesh Terms:

KEYWORDS: Sexually Transmitted Diseases

MESH TERMS: transmission

Chemical & Substance for Abstract: Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users.

AFFILIATION: Institute for International Research on Youth at Risk, National Development and Research Institutes, Inc., New York, NY 10010, USA. neaigus@ndri.org

Country: United States

AGENCY: United States NIDA

GRANT: DA09920

ACRONYM: DA

MEDLINETA: J Infect Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users Related Publications

• 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam.
• Data and Public Health Decision Making on HIV Prevention in Injection Drug Users.
• Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment.
• High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs.
• Patients in long-term maintenance therapy for drug use in Italy: analysis of some parameters of social integration and serological status for infectious diseases in a cohort of 1091 patients.
• Positive deviance control-case life history: a method to develop grounded hypotheses about successful long-term avoidance of infection.
• Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States of America.
• Reducing syringe sharing among injecting drug users in Winnipeg: 81% success or 19% failure?
• Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users.